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ABSTRACT
Genomically amplified fibroblast growth factor receptor 1 (FGFR1) is an 
oncogenic driver in defined lung cancer subgroups and predicts sensibility against 
FGFR1 inhibitors in this patient cohort. The FGFR inhibitor nintedanib has recently 
been approved for treatment of lung adenocarcinoma and is currently evaluated for 
small cell lung cancer (SCLC). However, tumor recurrence due to development of 
nintedanib resistance might occur. Hence, we aimed at characterizing the molecular 
mechanisms underlying acquired nintedanib resistance in FGFR1-driven lung cancer. 
Chronic nintedanib exposure of the FGFR1-driven SCLC cell line DMS114 (DMS114/
NIN) but not of two NSCLC cell lines induced massive overexpression of the 
multidrug-resistance transporter ABCB1. Indeed, we proved nintedanib to be both 
substrate and modulator of ABCB1-mediated efflux. Importantly, the oncogenic FGFR1 
signaling axis remained active in DMS114/NIN cells while bioinformatic analyses 
suggested hyperactivation of the endothelin-A receptor (ETAR) signaling axis. Indeed, 
ETAR inhibition resensitized DMS114/NIN cells against nintedanib by downregulation 
of ABCB1 expression. PKC and downstream NFκB were identified as major downstream 
players in ETAR-mediated ABCB1 hyperactivation. Summarizing, ABCB1 needs to be 
considered as a factor underlying nintedanib resistance. Combination approaches 
with ETAR antagonists or switching to non-ABCB1 substrate FGFR inhibitors represent 
innovative strategies to manage nintedanib resistance in lung cancer.
INTRODUCTION
Lung cancer is the leading cause of cancer death 
worldwide [1, 2]. Due to detection at rather advanced 
stages, accompanied by intrinsic chemoresistance in non-
small cell lung cancer (NSCLC) and rapid metastasis 
and therapy resistance development in small cell lung 
cancer (SCLC) as well as frequent relapse after surgical 
intervention, prognosis of this disease is very poor [3-5]. 
For these reasons it is clear that new strategies for rational 
treatment of lung cancer are urgently needed.
The fibroblast growth factor (FGF)/FGF receptor 
(FGFR) signaling axis is an essential system playing 
major roles in embryonic development and adult tissue 
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homeostasis [6-8]. Signaling via the FGFR axis regulates 
gene expression important for cellular mechanisms such as 
proliferation, migration, survival and differentiation [8, 9]. 
In many tissue types, aberrant FGFR signaling has been 
described to promote cancer development [6, 10, 11]. The 
FGFR1 gene is amplified in defined subgroups of both 
NSCLC and SCLC and proved to be a driving oncogene 
in a substantial subgroup of patients suffering from 
these cancer types [12, 13]. Intense research is ongoing 
regarding strategies to target oncogenic FGFR1 and 
several clinical trials to evaluate the efficacy of various 
FGFR inhibitors in patients with lung cancer are currently 
active or have already been completed [10, 14, 15].
Nintedanib is a selective small-molecule inhibitor 
of FGFR, vascular endothelial growth factor receptor 
(VEGFR) and platelet-derived growth factor receptor 
(PDGFR) that has recently been approved for second-
line treatment after chemotherapy failure in advanced 
lung adenocarcinoma [15, 16]. Currently, several trials 
employing nintedanib are also conducted in SCLC (www.
clinicaltrials.gov). Nevertheless, despite the initial success 
of FGFR1-targeting small molecule therapy, occurrence 
of acquired therapy resistance is one factor limiting the 
successful application of FGFR inhibitors in lung cancer 
[8, 17].
Data on mechanisms underlying therapy failure or 
resistance development with respect to small molecule 
FGFR inhibitors in lung cancer are limited. Therefore, 
this study aimed to dissect molecular factors underlying 
acquired FGFR inhibitor resistance in FGFR1-driven 
lung cancer. We have identified ATP-binding-cassette 
transporter B1 (ABCB1) overexpression as decisive 
mechanism for acquired nintedanib resistance in FGFR1-
driven SCLC but not NSCLC cell models. Additionally, 
we demonstrate that nintedanib is a substrate of ABCB1 
and, hence, this resistance mechanism needs to be 
considered as a factor limiting therapy response.
RESULTS
Selection of FGFR1-driven SCLC and NSCLC 
cell lines for nintedanib resistance
To investigate the molecular mechanisms underlying 
resistance against the FGFR inhibitor nintedanib, we 
selected one FGFR1-driven SCLC (DMS114) and 
two NSCLC cell lines (NCI-H1703, NCI-H520) for 
acquired nintedanib resistance. All these lung cancer cell 
lines bear amplification of the FGFR1 gene (shown for 
DMS114, Figure 1A) and have previously been shown 
to be hypersensitive to FGFR tyrosine kinase inhibition 
[13]. Exposure of cells over several months to constantly 
increasing nintedanib doses up to the low micromolar 
range resulted in pronounced acquired nintedanib 
resistance towards the selection drug (Figure 1B and 
Supplementary Figure S1). When seeded at low density, 
5μM nintedanib strongly reduced clone formation capacity 
of DMS114 cells (75% reduction of colony formation). 
In contrast, at an equal concentration of nintedanib, 
clone formation capability of DMS114/NIN cells was not 
affected (Figure 1C). Also, apoptosis/cell death induction 
by nintedanib was significantly reduced in the subline as 
compared to the parental cell line, indicated by a lower 
percentage of cells with positive Annexin V/PI staining 
(Figure 1D). When stimulated for 15 minutes with the 
ligand FGF2, FGFR1 downstream signaling in DMS114 
cells was massively activated as shown by elevated ERK 
and AKT phosphorylation. Preincubation of the cells with 
nintedanib for 1 hour completely blocked FGF2-mediated 
activation of FGFR1 signaling. In DMS114/NIN cells 
basal phosphorylation levels of FGFR1 downstream 
targets ERK and AKT were strongly increased and further 
enhanced by FGF2. In contrast to the parental cell line, 
nintedanib exposure of DMS114/NIN cells did not result 
in complete blockade of FGFR1-mediated downstream 
signaling (Figure 1E).
Nintedanib-resistant subclones maintain 
FGFR1-signaling as oncogenic driver
Sequencing of the kinase domain revealed no 
activating FGFR1 mutation in nintedanib-resistant 
DMS114/NIN cells (data not shown). To investigate the 
impact of resistance development on FGFR1 expression 
levels, qPCR and Western blot analyses were performed. 
FGFR1 expression levels were increased in the resistant 
DMS114/NIN subline both on mRNA (Figure 2A) 
and protein levels (Figure 2B). FISH analysis revealed 
genomic rearrangements of the FGFR1 amplicon 
during selection with loss of one FGFR1 gene copy on 
a derivative chromosome but gain of other strongly 
fluorescent FGFR1 signals indicative for homogeneously 
staining regions (HSR) (arrows in Figure 2C) in DMS114/
NIN cells. However, the overall FGFR1 gene dose 
remained unaltered after nintedanib selection (aCGH 
analysis in Figure 2D). In order to test functionality of 
FGFR1, the two cell lines were kept under serum-free 
conditions as well as stimulated with FGF2. Again, basal 
levels of FGFR1 protein were elevated both under serum-
containing and starved conditions in DMS114/NIN cells 
(Figure 2E). Interestingly, in the parental cell line FGF2 
induced a short-term upregulation of FGFR1 (at 5 minutes 
exposure) followed by downregulation. In contrast, in the 
DMS114/NIN subline upregulation of FGFR1 persisted 
distinctly longer (>30 minutes) and downregulation 
was not seen before 60 minutes exposure. Accordingly, 
activation of downstream signals such as the MAPK or 
the PI3K/AKT pathway was stronger and more uniform 
in DMS114/NIN cells (Figure 2E). In contrast, in the 
parental cell line FGF2-mediated phosphorylation of ERK 
and AKT exhibited early and late peaks at 5 min and 60 
min, respectively. DMS114/NIN cells exhibited no cross-
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Figure 1: Generation of a FGFR1-driven SCLC cell line with acquired nintedanib resistance. A. aCGH analysis was used 
to elucidate relative gene dose changes of DMS114 cells in comparison to normal human reference DNA. Results for the chromosome 
8p arm are shown and the FGFR1 gene locus is indicated by the arrow. B. Viability of DMS114 and DMS114/NIN cells was analyzed by 
MTT assay after 72 hours exposure to the indicated concentrations of nintedanib. *** p < 0.001, 2-way ANOVA, Bonferroni post-test. C. 
Impact of long-term (10d) nintedanib-exposure on clone formation capacity of DMS114 and DMS114/NIN cells was evaluated by crystal 
violet staining of fixed cells. Quantification was performed by densitometric measurement of stained cells using ImageJ software. Data are 
presented as relative values normalized to untreated controls. * p < 0.05, unpaired t-test. D. Apoptotic cell death induction was analyzed 
by Annexin V/PI-staining and FACS after 24 and 48 hours of 5μM nintedanib treatment of DMS114 and DMS114/NIN cells. ** p < 0.01 
and *** p < 0.001, unpaired t-test. E. Expression/phosphorylation of FGFR1 and selected downstream signaling proteins in DMS114 
and DMS114/NIN cells was analyzed by Western blot of total cell lysates of serum-starved cells, pre-incubated for 1h with the indicated 
concentration of nintedanib and stimulated for 15min with 20ng/ml FGF2. ß-actin was used as loading control.
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Figure 2: The FGFR1 signaling axis is maintained in DMS114/NIN cells upon selection for nintedanib resistance. A. 
FGFR1 mRNA expression level of DMS114/NIN cells was analyzed by quantitative RT-PCR. Data are given relative to parental cells. 
Expression levels were normalized to the housekeeping gene ACTB. *** p < 0.001, unpaired t-test. B. FGFR1 protein levels of DMS114 
and DMS114/NIN cells analyzed by Western blot. A representative experiment (upper panel) is opposed to the densitometric quantification 
of two independent experiments using ImageJ software (lower panel). FGFR1 protein levels were normalized to the housekeeping gene 
ß-actin and the parental cells are set as 1. *** p < 0.001, unpaired t-test. C. Copy number evaluation of the FGFR1 gene was performed 
by FISH. Representative metaphases of DMS114 and DMS114/NIN cells are shown. The light grey arrows indicate FGFR1, the dark grey 
arrows centromere 8. Chromosomes were visualized by DAPI. D. aCGH analysis was performed to depict relative FGFR1 gene doses 
of DMS114 and DMS114/NIN cells. The respective region on chromosome 8p11 is shown and the FGFR1 locus is indicated by arrows. 
E. Expression/phosphorylation of FGFR1 and selected downstream signaling proteins in DMS114 and DMS114/NIN cells was analyzed 
by Western blot of total cell lysates of serum-starved cells, stimulated with 10% FCS or 20ng/ml FGF2 for the indicated exposure times. 
ß-actin was used as loading control. F. Viability of DMS114 and DMS114/NIN cells was analyzed by MTT assay after 72 hours exposure 
to the indicated concentrations of ponatinib.
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resistance towards ponatinib - another FGFR inhibitor 
(Figure 2F). Together, this suggests that, despite constant 
selection pressure of nintedanib, the FGFR1 signaling axis 
is still maintained or even upregulated as an oncogenic 
driver in the DMS114/NIN subline.
A chemical screen reveals a multidrug resistance 
(MDR) phenotype in DMS114/NIN cells
To investigate the impact of acquired nintedanib 
resistance on the sensitivity against other cancer drugs, a 
high-throughput screen employing a library of approved 
and experimental compounds was performed. This screen 
revealed distinct cross-resistance of the DMS114/NIN 
subline against several anticancer agents (red symbols 
in Figure 3A) including e.g. vincristine, vinblastine, 
mitoxantrone, docetaxel, carfilzomib as well as the small 
molecule EGFR inhibitor CUDC-101. Noteworthy, all 
these compounds are known substrates of ABC transporter 
drug efflux pumps conferring a multidrug resistance 
(MDR) phenotype.
Transcriptional upregulation of ABCB1 
underlies the MDR phenotype of DMS114/NIN 
cells
These results prompted us to perform whole-genome 
gene expression arrays to detect mRNA expression 
differences of genes potentially causing the observed 
MDR phenotype. Regarding all ABC transporter efflux 
pumps, only expression of ABCB1 mRNA was distinctly 
enhanced in DMS114/NIN cells (Figure 3B), which 
is known to affect all cross-resistant drugs identified in 
the drug screen (Figure 3A). Significantly enhanced 
expression of this gene could be confirmed by qPCR 
(Figure 3C). Accordingly, high ABCB1 protein expression 
was confirmed by Western blot (Figure 3D). In contrast, 
neither ABCC1 nor ABCG2 - the two other highly 
important resistance-mediating ABC transporter genes – 
were expressed at detectable levels in DMS114/NIN cells 
(data not shown). To further elucidate whether ABCB1 
upregulation upon nintedanib selection is restricted to 
SCLC, we tested our two additional FGFR1-driven 
NSCLC cell lines (NCI-H1703/NIN, NCI-H520/NIN) 
with acquired nintedanib resistance. Despite identical 
conditions of in vitro selection, overexpression of ABCB1 
was only observed in DMS114/NIN cells (Figure 3D).
Next, we investigated whether ABCB1 expression 
in response to nintedanib is a consequence of immediate 
stress response. However, exposure of the parental cell 
line to 1μM nintedanib up to 48 hours did not induce 
detectable levels of ABCB1 expression (Figure 3E). 
Removal of nintedanib selection pressure for up to 40 days 
resulted in gradual loss of ABCB1 expression in DMS114/
NIN cells (Figure 3F), leading to a significant attenuation 
of resistance in the revertant cell line towards nintedanib 
and vincristine. Nevertheless, resistance remained highly 
significant after this period without selection pressure 
(Supplementary Figure S2A and S2B).
Inhibition of ABCB1 resensitizes DMS114/
NIN cells to nintedanib as well as other MDR 
substrate drugs
Next, we investigated whether pharmacological 
inhibition of ABCB1 restores sensitivity of DMS114/
NIN cells towards nintedanib as well as known ABCB1 
substrate drugs. Presence of the third generation ABCB1 
inhibitor elacridar (10μM), itself not influencing 
cell viability, almost completely abrogated acquired 
nintedanib resistance of DMS114/NIN cells (Figure 4A 
and Supplementary Figure S3A). Elacridar is known 
to inhibit also the ABCG2 efflux pump. However, 
microarray data and Western blotting suggested very low 
and unaltered ABCG2 expression levels in DMS114/
NIN cells as compared to the parental cell line (data not 
shown). This suggests that ABCB1 activity negatively 
interferes with nintedanib cytotoxicity, possibly by direct 
efflux. Accordingly, transfection of parental cells with an 
ABCB1-encoding expression vector led to a significantly 
reduced sensitivity towards nintedanib (Supplementary 
Figure S3B, S3C). DMS114/NIN cells also exhibited 
pronounced cross-resistance against the investigated 
ABCB1 substrates vincristine, vinblastine and doxorubicin 
(Supplementary Figure S4A, S4B and S4C, respectively). 
Coincubation with elacridar resensitized the subline to the 
tested drugs, while having no effect on the cytotoxicity 
in the parental cells (Supplementary Figure S4). With 
regard to FGFR1-downstream signaling in response to 
FGF2, cotreatment with elacridar led to restoration of 
ERK and AKT phosphorylation inhibition by nintedanib 
in the DMS114/NIN subline (Figure 4B). Accordingly, 
intracellular levels of nintedanib were strongly reduced in 
DMS114/NIN as compared to DMS114 cells after short-
term exposure (Figure 4C). However, in the presence 
of elacridar, intracellular nintedanib levels of DMS114/
NIN, but not the parental cells were distinctly increased, 
proving that nintedanib is a substrate of ABCB1-mediated 
drug efflux.
Additionally, we tested whether nintedanib 
is an inhibitor of ABCB1 using the fluorescent dye 
Rh123 as substrate (Supplementary Figure S5A). As 
expected, accumulation of Rh123 was significantly 
reduced in DMS114/NIN as compared to DMS114 cells. 
Nintedanib moderately but significantly enhanced Rh123 
accumulation in the selected subline, however, to a 
distinctly lesser extent than did elacridar. This indicates 
that nintedanib is a weakly competitive inhibitor of 
ABCB1-mediated Rh123 export. In contrast, ABCB1-
driven efflux of calcein AM was inhibited with similar 
Oncotarget50166www.impactjournals.com/oncotarget
Figure 3: DMS114/NIN cells develop a MDR phenotype upon nintedanib selection due to upregulation of ABCB1. A. 
Sensitivities of DMS114 and DMS114/NIN cells towards different anticancer drugs were tested in a large-scale cytotoxicity screen evaluated 
by CellTiter Glo assay after 72 hours drug exposure. Sensitivities of DMS114 and DMS114/NIN cells are plotted as area under the curve 
(AUC) values determined from 8-point dose-response curves to individual drugs. Green symbols represent drugs less active in DMS114, 
red symbols represent drugs less active in DMS114/NIN cells. Triangles indicate compounds that were highly active in DMS114 cells with 
IC50 values below the lowest tested concentrations. Vertical error bars indicate SD of AUC of DMS114/NIN, horizontal error bars show 
SD of AUC of parental cells, respectively. Known ABCB1 substrate drugs are indicated by the numbers: 1) carfilzomib; 2) vinblastine; 3) 
vincristine; 4) mitoxantrone; 5) docetaxel; 6) CUDC-101; B. Whole-genome gene expression patterns of DMS114 and DMS114/NIN cells 
were established by microarray analysis and data were processed using GeneSpring software (Agilent Technologies). Raw and normalized 
mRNA expression values are depicted for ABCB1. C. ABCB1 mRNA expression was analyzed by quantitative RT-PCR and data are given 
normalized to ACTB mRNA expression. *** p<0.001, unpaired t-test. ABCB1-overexpressing SW480Tria cells served as positive control 
and were set as 100 (dashed line). n.d., not detected; D. ABCB1 protein expression levels of DMS114 (SCLC), NCI-H1703 and NCI-H520 
(both NSCLC SCC) and its respective nintedanib-selected sublines were determined by Western blot. ß-actin was used as loading control. 
E. Impact of short-term (24 and 48 hours) nintedanib exposure on ABCB1 expression in DMS114 and DMS114/NIN cells was analyzed 
by Western blot analysis. ß-actin was used as loading control. F. Impact of removal of nintedanib selection pressure on ABCB1 expression 
levels in DMS114/NIN cells was analyzed by Western blot analysis over 40 days. ß-actin was used as loading control.
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Figure 4: Nintedanib is a substrate of ABCB1-mediated drug efflux. A. Impact of the ABCB1 modulator elacridar on the 
anticancer activity of nintedanib in DMS114 and DMS114/NIN cells was measured by MTT assay after 72 hours drug exposure. *** 
p<0.001, 2-way ANOVA, Bonferroni post-test. B. The impact of the ABCB1 modulator elacridar on nintedanib-mediated inhibition of 
FGFR1 downstream target phosphorylation in DMS114 and DMS114/NIN cells was analyzed by Western blot. Serum-starved cells were 
treated with indicated concentrations of nintedanib or elacridar for 1h and stimulated with 10% FCS or 20ng/ml FGF2 for 15min. ß-actin 
was used as loading control. C. Intracellular levels of nintedanib in DMS114 and DMS114/NIN cells after 10 or 60min exposure to 1μM of 
the drug in the presence or absence of 5μM elacridar was determined by LC-MS. ** p < 0.01, *** p < 0.001, unpaired t-test. D. Impact 
of nintedanib on intracellular accumulation of the fluorescent ABCB1 substrate calcein. DMS114 and DMS114/NIN cells were incubated 
with calcein AM for 15min in the presence or absence of 10μM nintedanib. The ABCB1 modulators verapamil and elacridar served as 
positive controls. Intracellular calcein fluorescence was measured by FACS and analyzed by FlowJo software. * p < 0.05, ** p < 0.01, 
*** p < 0.001, unpaired t-test. E. Impact of nintedanib on the ABCB1 ATPase function was determined using ABCB1-enriched Sf9 cells. 
Crude Sf9 cell membrane vesicles were exposed to indicated concentrations of nintedanib in presence or absence of ATPase inhibitor 
vanadate. ATPase activation was measured through colorimetric quantification of liberation of inorganic phosphate. ATPase activation by 
30μM verapamil served as positive control. * p < 0.05, unpaired t-test. Vera= verapamil, Elac= elacridar, Nin= nintedanib;
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potency by elacridar, verapamil and nintedanib, suggesting 
a preferential binding of nintedanib to the calcein AM 
binding site of ABCB1 (Figure 4D). Moreover, nintedanib 
dose-dependently stimulated the ATPase activity of 
ABCB1 in Sf9 crude membrane extracts with a maximum 
effect at the highest tested dose (10μM), where nintedanib 
exhibited a potency almost comparable with the positive 
control verapamil (Figure 4E) [18].
Selection of DMS114 cells for resistance against 
another FGFR tyrosine kinase inhibitor (TKI) 
also leads to upregulation of ABCB1
We were interested whether selection of DMS114 
for acquired resistance against other FGFR inhibitors 
susceptible to ABCB1-mediated drug efflux might also 
result in ABCB1 upregulation. We, thus, first evaluated 
the sensitivities of DMS114/NIN cells and their parental 
cell line towards other FGFR TKIs. Interestingly, 
DMS114/NIN cells exhibited marked resistance towards 
the small molecule inhibitor AZD4547, which could be 
reversed by coincubation with elacridar. This suggests 
that AZD4547 is a substrate for ABCB1-mediated efflux 
(Figure 5A). Based on these findings, we established 
a subline of DMS114 cells with acquired resistance 
towards AZD4547 (DMS114/AZD; Figure 5B). After 
several weeks of constant drug exposure, qPCR analysis 
revealed significantly elevated ABCB1 expression levels 
in DMS114/AZD cells (Figure 5C). Elacridar significantly 
diminished AZD4547 resistance of DMS114/AZD cells 
(Figure 5B). Together, these data suggest that chronic 
exposure of DMS114 cells to ABCB1 substrate FGFR 
inhibitors generally leads to ABCB1-mediated resistance 
acquisition.
Figure 5: Selection of DMS114 cells for acquired AZD4547 resistance also mediates ABCB1 upregulation. A. Impact of 
the ABCB1 modulator elacridar on the anticancer activity of AZD4547 in DMS114 and DMS114/NIN cells was measured by MTT assay 
after 72 hours drug exposure. *** p<0.001, 2-way ANOVA, Bonferroni post-test. B. Viability of DMS114, DMS114/NIN and DMS114/
AZD cells was analyzed by MTT assay after 72 hours exposure to the indicated concentrations of AZD4547. *** p < 0.001, 2-way 
ANOVA, Bonferroni post-test. C. ABCB1 mRNA expression was analyzed by quantitative RT-PCR and data are given normalized to ACTB 
mRNA expression. ** p < 0.01, *** p<0.001, unpaired t-test.
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Nintedanib resensitizes an independent MDR 
model to ABCB1 substrate drugs
We further raised the question whether nintedanib 
could also reverse ABCB1-mediated drug resistance in an 
independent MDR model. Therefore, we tested the cervix 
carcinoma cell line KB-3-1 and its ABCB1-overexpressing 
sublines KBC-1 and KB-V1 [19] for sensitivity against 
vincristine (Figure 6A) and vinblastine (Supplementary 
Figure S5B) in absence and presence of nintedanib. While 
having only minor effects on the cytotoxicity in KB-3-1, 
5μM nintedanib partially restored sensitivity towards both 
vincristine and vinblastine in KBC-1 cells. Accordingly, 
10μM nintedanib moderately but significantly increased 
intracellular accumulation of calcein in KBC-1 
cells (Figure 6B). This effect was also observed for 
accumulation of Rh123 (Supplementary Figure S6A). In 
Figure 6: Nintedanib resensitizes multidrug resistant KBC-1 cells to ABCB1 substrate drugs. A. Viability of KB-3-1 and 
KBC-1 was analyzed by MTT assay after 72 hours exposure to vincristine in the presence or absence of 5μM nintedanib. Verapamil (lower 
panels) was used as positive control for ABCB1 modulation. *** p<0.001, 2-way ANOVA, Bonferroni post-test. B. Impact of nintedanib 
on intracellular accumulation of the fluorescent ABCB1 substrate calcein was determined. KB-3-1 and KBC-1 cells were incubated with 
calcein AM for 15 minutes in the presence or absence of 10μM nintedanib. Intracellular calcein fluorescence was measured by FACS 
and analyzed by FlowJo software. The ABCB1 modulators verapamil and elacridar served as positive controls. * p < 0.05, ** p < 0.01, 
*** p < 0.001, unpaired t-test. Vera= verapamil, Elac= elacridar, Nin= nintedanib;
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addition, inhibition of ABCB1 by elacridar resensitized 
KBC-1 and KB-V1 cells against high doses of nintedanib 
(Supplementary Figure S6B and S6C).
Lack of ABCB1 gene amplification and promoter 
methylation changes in DMS114/NIN cells
Genetic amplification of the ABCB1 locus is 
frequently observed in MDR cell lines selected against 
cytotoxic anticancer drugs [20]. However, we found 
no ABCB1 gene dose alteration in DMS114/NIN cells 
by indirect aCGH (Figure 7A). Decreased methylation 
of seven CpG dinucleotides in the ABCB1 promoter 
downstream the transcription start site (from +524 to +587) 
was previously found to be associated with enhanced 
gene expression [21]. However, DNA methylation of all 
these CpG dinucleotides was below the pyrosequencing 
limit of quantification in both the parental DMS114 cells 
and the resistant subline (data not shown). This suggests 
that neither gene amplification nor epigenetic regulation 
by altered promoter methylation cause upregulation of 
ABCB1 gene expression in DMS114/NIN cells.
Endothelin-A receptor signaling contributes to 
ABCB1 overexpression in DMS114/NIN cells
In search of transcriptional alterations potentially 
underlying ABCB1 upregulation, gene expression data 
of DMS114 and DMS114/NIN cells were compared by 
GSEA. Noteworthy, several enriched gene ontology (GO) 
terms within the cellular pathway-, protein interaction- 
as well as the reactome-databases concerned G-protein 
coupled receptor signaling. These GO terms included the 
endothelin pathway, GPCR-ligand binding, peptide ligand 
binding receptors as well as rhodopsin-like receptors, all 
containing members of the endothelin signaling family 
(Supplementary Figure S7A-S7D). Subsequent analysis 
on the single gene level revealed endothelin-1 (EDN1/
ET-1) and the respective endothelin-A receptor (EDNRA/
ET
A
R) to be among the top upregulated genes in DMS114/
NIN cells (Figure 7B-7D). Endothelin signaling has 
been reported to activate ABCB1 expression in brain 
capillary endothelial cells via endothelin receptors A and 
B via activation of PKC and subsequently NFκB [22]. 
Transcriptional upregulation of EDNRA in DMS114/NIN 
cells was validated by qRT-PCR (Figure 7E) and elevated 
levels of both ET-1 and ET
A
R were also confirmed on 
protein level (Figure 7F). Interestingly, nintedanib-
selected sublines of NCI-H1703 and NCI-H520 cells, 
both lacking ABCB1 overexpression, also exhibited 
low and unaltered ET
A
R and ET-1 expression levels as 
compared to their parental cell lines (Figure 7E and 7F). 
Accordingly, blockade of this receptor with its specific 
antagonist tezosentan for 72 hours led to a distinct 
decrease in ABCB1 protein levels in DMS114/NIN cells 
(Figure 8A) supporting a role in transcriptional ABCB1 
activation. Interestingly, both ET
A
R downstream effectors 
PKC and NFκB p65 tended to be hyperphosphorylated 
and, hence, hyperactivated in DMS114/NIN as compared 
to DMS114 cells. ET
A
R blockade by tezosentan abolished 
phosphorylation of both PKC isotypes and NFκB p65 in 
the nintedanib-resistant subline (Figure 8A). Antagonism 
of ET
A
R by tezosentan also led to a significant re-
sensitization of DMS114/NIN cells towards nintedanib, 
while having only a minor effect in the parental cell 
line (Figure 8B). In line with these findings, partial 
PKC knockdown by siRNA resulted in decreased levels 
of ABCB1, pNFκB p65 and a significantly increased 
cytotoxicity of nintedanib in DMS114/NIN cells (Figure 
8C and 8D, respectively). A comparably increased 
sensitivity of DMS114/NIN cells towards nintedanib and 
vincristine was also observed upon co-incubation with 
the pharmacological PKC inhibitor BIMI (Supplementary 
Figure S8A and S8B, respectively). Accordingly, also 
blockade of NFκB by the selective inhibitor QNZ for 48 
hours resulted in downregulation of ABCB1 (Figure 8E). 
In summary, this suggests that transcriptional upregulation 
of ABCB1 in DMS114/NIN cells upon selection for 
nintedanib resistance is induced at least in part by an 
ET
A
R-mediated activation of the PKC-NFκB signaling 
pathway (summarized in Figure 8F).
DISCUSSION
The FGFR1 gene is amplified in lung cancer at 
varying frequencies (depending on the histological subtype 
between 5.6% and 19% for SCLC and NSCLC SCC, 
respectively) and overexpression of FGFR1 was shown to 
be a driving oncogenic factor in subgroups across all lung 
cancer subtypes [23-26]. Nintedanib, a small-molecule 
FGFR/PDGFR/VEGFR TKI, demonstrated efficacy in 
clinical trials against lung cancer and is approved for 
second-line treatment of lung adenocarcinoma [15]. 
Additionally, it is currently being evaluated clinically in 
SCLC [5]. As observed for all targeted anticancer agents, 
treatment of lung cancer patients with nintedanib is not 
curative and leads to disease recurrence due to acquired 
resistance development [15, 16]. Therefore, we were 
interested in elucidating the molecular mechanisms 
underlying acquired insensitivity of FGFR1-driven 
SCLC and NSCLC against nintedanib. Out of the three 
nintedanib-refractory cell models generated, the SCLC 
cell line DMS114/NIN was characterized by a cross-
resistance pattern in an extended drug screen with 
insensitivity against several chemotherapeutics but also 
TKIs. This phenotype resembles a phenomenon known as 
multidrug resistance (MDR) which is frequently based on 
the overexpression of pleiotropic efflux pumps of the ATP-
binding-cassette (ABC) transporter family (particularly of 
ABCB1, ABCG2 and ABCC1) [27-29]. Our subsequent 
analyses confirmed that massive overexpression of 
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Figure 7: The endothelin-A receptor (ETAR) signaling axis contributes to ABCB1 upregulation in DMS114/NIN cells. 
A. Relative ABCB1 gene dose of DMS114/NIN as compared to their parental cell line was evaluated by indirect aCGH analysis. A part 
of chromosomal region 7q21 is shown and the ABCB1 gene locus depicted by the arrow. B. GSEA revealed significant enrichment of the 
pathway interaction database-derived GO term ‘endothelin-pathway’ for upregulation in DMS114/NIN as compared to DMS114 cells. 
The 20 most upregulated genes are depicted as heatmap and identified endothelin-1 (EDN1/ET-1) and endothelin-A receptor (EDNRA/
ET
A
R) to be among the top upregulated genes in DMS114/NIN cells (indicated by arrows). C, D. Raw and normalized mRNA expression 
values of the endothelin signaling family members revealed selective upregulation of genes encoding endothelin-A receptor (EDNRA) (C) 
and endothelin-1 (EDN1) (D). Data were analyzed using GeneSpring (Agilent Technologies) and GSEA softwares. E. mRNA expression 
levels of ET
A
R (EDNRA) in DMS114, NCI-H1703, NCI-H520 cells and their respective sublines were determined by quantitative RT-PCR. 
** p<0.01, one-sample t test; n.s., not significant; n.d., not detected before qPCR cycle 36; F. ET
A
R and ET-1 protein levels in DMS114, 
NCI-H1703 and NCI-H520 cells and their respective sublines were analyzed by Western blot. ß-actin was used as loading control.
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Figure 8: Inhibition of the PKC/NFκB signaling axis downregulates ABCB1 and resensitizes DMS114/NIN cells 
towards nintedanib. A. Impact of ET
A
R blockade by its antagonist tezosentan on expression and phosphorylation levels of indicated 
proteins in DMS114 and DMS114/NIN cells was analyzed by Western blot. ß-actin was used as loading control. B. Impact of ET
A
R blockade 
on viability of nintedanib-treated DMS114 and DMS114/NIN cells was measured by MTT assay. Cells were pretreated for 72 hours with 
50μM tezosentan. Viability was measured after another 72 hours exposure to nintedanib in combination with tezosentan. *** p<0.0001, 
2-way ANOVA, Bonferroni post-test. C, D. Transient knockdown of PKC was performed in DMS114 and DMS114/NIN cells by siRNA 
transfection. C. Impact of 50nM siPKC knockdown in DMS114/NIN cells on PKCα protein levels and phosphorylation of indicated PKC 
downstream targets was analyzed by Western blot 48 and 72 hours post-transfection. 50nM non-targeted siRNA (scr) served as transfection 
control. D. Impact of transient PKC knockdown on viability of DMS114 and DMS114/NIN cells after 72 hours exposure to nintedanib was 
analyzed by MTT assay. Cells pretreated with 50nM scrambled siRNA served as transfection control. E. Impact of NFκB inhibition by QNZ 
for 24 and 48 hours on ABCB1 expression in DMS114 and DMS114/NIN cells was determined by Western blot analysis. ß-actin was used 
as loading control. *** p<0.001, 2-way ANOVA, Bonferroni post-test. F. Schematic representation showing the mechanism of acquired 
resistance of DMS114 cells towards nintedanib.
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ABCB1 is underlying the MDR phenotype and nintedanib 
resistance of DMS114/NIN cells.
ABC transporters are transmembrane proteins 
which translocate a wide range of substances across 
cellular membranes [20]. One of their most important 
functions represents the protection of tissues from 
toxins and xenobiotics. Different ABC transporter 
subtypes are expressed on various non-malignant tissue 
types functioning as protective barriers in the body, 
including amongst others the endothelial layer of the 
cerebral microvasculature and the epithelial lining of the 
intestinal tract [30]. Substrates of ABC-mediated efflux 
include a wide range of biological compounds but also 
chemotherapeutics and targeted anticancer agents such 
as EGFR inhibitors [31, 32]. However, knowledge of the 
impact of ABC transporters on resistance against FGFR 
TKIs is limited. So far, only reversal of ABCB1-mediated 
MDR by the pan-FGFR/VEGFR inhibitor PD173074 and, 
in agreement with our here presented data, also nintedanib 
has been described [33, 34]. In the current study we 
demonstrate that high level expression of ABCB1 is 
underlying acquired nintedanib resistance of the FGFR1-
driven SCLC cell line DMS114 but not of the two NSCLC 
cell lines NCI-H1703 and NCI-H520. Furthermore, we 
proved that nintedanib is a direct substrate of ABCB1. 
Importantly, nintedanib was also able to restore sensitivity 
of DMS114/NIN cells, colchicine-selected KBC-1 [35] 
and vinblastine-selected KB-V1 cells towards other 
ABCB1 substrate compounds leading to synergistic 
effects in combination experiments especially in a FGFR-
driven background. It is of interest why the upregulation 
of ABCB1 expression in response to nintedanib treatment 
occurred exclusively in the SCLC and not in the two 
NSCLC cell lines. The marked propensity of SCLC 
to develop chemoresistance in response to anticancer 
therapy has been described to be -at least partly- mediated 
by overexpression of ABC transporters [36]. However, 
upregulation of ABCB1 expression in lung cancer does 
not appear to be exclusive for SCLC, as it has also been 
observed in NSCLC following chemotherapy [37]. 
With respect to targeted small molecule inhibitors, no 
connection between lung cancer subtypes and ABCB1 
induction has been described. So far, only overexpression 
of ABCG2 in healthy bronchiolar progenitor cells has 
been observed to mediate efficient drug efflux. However, 
at present there is no data on ABCB1 expression levels 
in pulmonary neuroendocrine cells, the non-malignant 
SCLC counterpart. Therefore, it will be interesting to 
elucidate whether ABCB1 overexpression during selection 
of DMS114 for acquired resistance reflects a SCLC cell 
type-specific response to nintedanib treatment.
While ABCB1-mediated resistance acquisition is 
frequently observed as a consequence of the selection 
against chemotherapeutic agents, the examples regarding 
TKI resistance are comparably sparse. Reports started 
with ABCB1 and ABCG2 overexpression in Philadelphia 
chromosome-positive chronic myeloid leukemia cells as 
a consequence of imatinib selection [38]. Recently, also 
acquisition of EGFR and MET inhibitor resistance was 
occasionally connected with ABCB1 overexpression 
and concerned afatinib and erlotinib as well as PHA-
665752, respectively [39, 40]. In the case of afatinib 
and PHA-665752 resistance, upregulation of ABCB1 
expression was connected with selection for a cancer 
stem cell phenotype and an epithelial-to-mesenchymal 
transition (EMT) switch [41]. In our study, however, 
selection of a DMS114 cell subclone with enhanced 
stemness during nintedanib selection seems unlikely. 
Gene set enrichment analysis (GSEA) did not indicate 
any upregulation of stem cell markers. Furthermore, 
DMS114/NIN cells exhibited rather reduced than 
enhanced growth as three-dimensional spheroids in 
vitro and as subcutaneous xenografts in vivo (data not 
shown).
In search of factors underlying the massive ABCB1 
upregulation, GSEA suggested hyperactivation of several 
G-coupled protein receptor pathways in DMS114/NIN 
cells. At a closer look, it turned out that all of these GO 
terms contained the soluble polypeptide ligand ET-1 and 
its cognate G-protein-coupled receptor ET
A
R. Indeed, the 
ET-1/ET
A
R signaling axis, with its downstream effectors 
PKC and NFκB, was hyperactivated in DMS114/NIN 
cells and significantly contributed to acquired nintedanib 
resistance. Hence, antagonism of ET
A
R by tezosentan 
led to decreased levels of ABCB1 protein accompanied 
by decreased PKC and NFκB phosphorylation and, 
importantly, to a significant re-sensitization of DMS114/
NIN cells towards nintedanib. The endothelin signaling 
axis represents a promising therapy target based on 
various protumorigenic effects. These include, amongst 
others, epithelial-to-mesenchymal transition (EMT) and, 
importantly, chemoresistance by induction of stemness 
features [42]. However, neither enrichment of an EMT nor 
a stem cell signature was suggested by our bioinformatic 
analyses in DMS114/NIN cells. Interestingly, Bauer and 
colleagues suggested an essential contribution of the ET-1/
ET
A
R signaling axis to constitutive ABCB1 expression in 
brain capillary endothelial cells as a functional component 
of the blood-brain-barrier [22]. The authors additionally 
found ABCB1 expression to be induced by ET
A
R through 
activation of PKC and NFκB downstream signaling. 
In the light of our here presented data, this implies that 
cancer cells can utilize physiological signal circuits, as in 
this case ABCB1 activation by ET-1/ET
A
R signaling in 
endothelial cells, to survive systemic treatment options. 
Activation of MDR by this particular physiological 
brain protection mechanism has not been reported in the 
malignant background so far. One might hypothesize that 
ET
A
R-mediated ABCB1 activation is a consequence of the 
specific nintedanib target profile including major players 
in endothelial cell physiology like FGFR and VEGFR. 
Indeed, in a study by Huang et al., selection against the 
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VEGFR/PDGFR angiokinase inhibitor sunitinib led to 
induction of ABCB1 expression in transformed HMEC-
1 endothelial cells [43]. Alternatively, based on the 
dominance of gene amplification and epigenetic regulation 
in ABCB1-mediated MDR, the impact of such more subtle 
physiological mechanisms might have been overlooked 
so far in the malignant background. Nevertheless, 
upregulation of both ET
A
R/ET-1 and ABCB1 was 
not observed in two FGFR-driven NSCLC cell lines, 
suggesting a possible impact of the SCLC histology.
Concerning the clinics, the fact that nintedanib is 
an ABCB1 substrate might impair its efficacy as a single 
treatment not only in lung cancer, but also in other cancer 
types. For instance, high intrinsic ABCB1 expression 
in clear cell renal carcinoma might render nintedanib 
treatment ineffective [44]. Additionally, the constitutive 
expression of ABC transporters at the blood brain barrier 
might limit applicability of nintedanib in cancers of the 
central nervous system [45]. On the contrary, nintedanib 
might function as a MDR reverser within combination 
treatment schemes, thus impeding chemotherapy-induced 
drug resistance. Moreover, combination approaches with 
ET
A
R antagonists or a switch to non-ABCB1 substrate 
FGFR inhibitors represent innovative strategies to manage 
nintedanib resistance in lung cancer.
MATERIALS AND METHODS
Cell culture
The human SCLC cell line DMS114 and the NSCLC 
cell lines NCI-H1703 and NCI-H520 were obtained from 
American Type Culture Collection (Manassas, VA). The 
human cervix carcinoma cell line KB-3-1, its colchicine-
resistant, ABCB1-overexpressing subline KBC-1 and its 
vinblastine-resistant, ABCB1-overexpressing subline KB-
V1 were a generous gift from Dr. Shen, Bethesda, USA 
[35]. KB-V1 cells were grown in DMEM, all other cell 
lines were cultured in RPMI 1640 media supplemented 
with 10% fetal calf serum. All cell lines were authenticated 
by array comparative genomic hybridization and regularly 
checked for Mycoplasma contamination (Mycoplasma 
Stain kit, Sigma, St. Luis, USA).
Drugs and chemicals
Nintedanib, ponatinib, AZD4547, PD173074 
and QNZ were purchased from Selleckchem (Munich, 
Germany), bisindolylmaleimide I (BIMI) from Cayman 
Chemical (Michigan, USA), FGF2 from Eubio (Peprotech, 
Rocky Hill, USA), verapamil from Abbott (Illinois, 
USA), Calcein AM from eBioscience (San Diego, USA), 
vanadate, elacridar, vincristine, vinblastine, doxorubicin 
from Sigma. Tezosentan was obtained from Actelion 
Pharm, Allschwil, Switzerland.
Selection of DMS114 cells for acquired 
nintedanib and AZD4547 resistance
DMS114, NCI-H1703 and NCI-H520 sublines were 
generated by constant in vitro exposure to submicromolar 
doses of nintedanib. In regular intervals, drug dose was 
continuously elevated, reaching a maximum dose of 
10μM after approximately 1 year. Nintedanib-resistant 
sublines were designated DMS114/NIN, NCI-H1703/
NIN and NCI-H520/NIN. The AZD4547-selected subline 
of DMS114 cells was termed DMS114/AZD. Resistance 
levels were constantly monitored by cell viability assay 
(MTT).
Array comparative genomic hybridization 
(aCGH)
aCGH was performed on 4x44K oligonucleotide-
based microarrays (Agilent, Santa Clara, USA) as 
previously described [46]. DNA labeling and hybridization 
was performed according to the manufacturer’s 
instructions. For direct aCGH, DMS114 was compared 
to normal human reference DNA, for indirect aCGH, 
DMS114/NIN was compared directly to its parental line 
DMS114.
Cell viability assay
To determine cell viability, 3x104 cells were seeded 
in 96-well plates and allowed to adhere for 24 hours. Cells 
were exposed to test compounds and after 72 hours, cell 
survival was determined by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT)-based vitality 
assay (EZ4U, Biomedica, Vienna, Austria) according to the 
manufacturer’s instructions. Dose-response curves were 
generated by GraphPad Prism software and cytotoxicity 
levels were expressed as IC50 values, indicating drug 
concentrations resulting in a 50% reduction of cell number 
in comparison to untreated controls.
Clone formation assay
To determine the ability of single cells for clonal 
expansion at low density in the presence of nintedanib, 
5x102 cells were seeded in 24-well plates and were 
allowed to adhere for 24 hours. Clone formation under 
exposure with indicated drug concentrations was followed 
for 10 days. Cells were fixed with ice-cold methanol and 
stained with crystal violet. Degree of clonal expansion was 
determined by colorimetric quantification of stained cells 
using ImageJ software.
Annexin V/propidium iodide (PI) staining and 
FACS analysis
To determine apoptosis (Annexin V, BD 
Biosciences, Franklin Lakes, USA) and cell death (PI, 
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Sigma, USA) induction, cells were treated with indicated 
concentrations of nintedanib for 24 and 48 hours. Cells 
were trypsinized and stained with APC-labeled Annexin 
V and PI and subjected to FACS analysis (FACScalibur, 
Becton Dickinson, Palo Alto, USA). Extent of apoptosis/
cell death induction was analyzed by FlowJo software.
RNA isolation and real-time PCR
Total RNA from cell lysates was isolated by Trizol 
reagent (Life Technologies, Carlsbad, USA). mRNA 
was reverse transcribed (Thermo Fisher Scientific, 
Waltham, USA) and resulting cDNA was used to 
perform TaqMan quantitative real-time PCR as described 
previously [47] using following primers: FGFR1 sense: 
5’-CCTCTTCTGGGCTGTGCT-3′, FGFR1 antisense: 
5’-CGGGCATACGGTTTGGTT-3’, ABCB1 sense: 
5′-CCCATCATTGCAATAGCAGG-3′. ABCB1 antisense: 
5′-GTTCAAACTTCTGCTCCTGA-3′, EDNRA sense: 
5'-GGGATCACCGTCCTCAACCT-3', EDNRA antisense: 
5'-CAGGAATGGCCAGGATAAAGG-3', ACTB sense: 
5′-GGATGCAGAAGGAGATCACTG-3′, ACTB 
antisense: 5′-CGATCCACACGGAGTACTTG-3′. ACTB 
served as internal control.
Western blot analysis
Protein extracts from total cell lysates were 
prepared, separated by SDS-PAGE and blotted onto 
polyvinylidene difluoride membranes (PVDF, Fisher 
Scientific). FGFR1, phospho-ERK1/2 (Thr202/Tyr204), 
ERK1/2, AKT, phospho-AKT, PKCα, pan-phospho-PKC, 
NFκB p65, pNFκB p65 and pPKC-substrate antibody 
were all purchased from Cell Signaling Technology 
(Danvers, USA). ß-actin monoclonal mouse AC-15 was 
obtained from Sigma and ABCB1 (C219) from BioLegend 
(San Diego, USA). Horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz Biotech, Dallas, USA) 
were used as 1:10.000 working dilutions.
Metaphase chromosome preparation and 
fluorescent in situ hybridization (FISH)
Metaphase chromosome spreads of DMS114 and 
DMS114/NIN cells were prepared by standard techniques. 
Chromosomes were co-denatured and hybridized with 
fluorophore-labeled FISH-probes (Abbott) targeting the 
FGFR1 locus as well as centromere chromosome 8 and 
subjected to fluorescence microscopic analysis.
Anticancer compound screen
A large-scale drug screen was performed in 384-
well plates on a cell::explorer platform (PerkinElmer, 
Waltham, Massachusetts, USA). In a pre-screen, DMS114, 
NCI-H1703, NCI-H520 cells and their respective 
nintedanib-selected sublines were tested against a set of 
549 compounds at a final concentration of 20μM (0.1% 
DMSO) measured in duplicates. 10μM vincristine served 
as positive control and was set to 0%. 0.1% DMSO served 
as negative control and was set to 100%. Compounds 
were transferred into drug plates by acoustic droplet 
ejection using an Echo 520 liquid handler (LABCYTE, 
Sunnyvale, CA, USA). Cells were seeded onto drug plates 
at a density of 1x103 cells/well. After 72h, cell viability 
was determined by CellTiter Glo Assay (Promega, 
Madison, USA) according to manufacturer's instructions 
on a EnVision plate reader (PerkinElmer). Data analysis 
was performed by calculating a percentage of control to 
normalize for variability across different plates. Signal 
intensities for the negative control DMSO wells were set to 
0%, wells containing the positive control vincristine were 
set to 100% for each plate individually. Hits were defined 
as compounds that gave > 50% inhibition compared to 
the DMSO controls. The pre-screen yielded 136 positive 
hits. In a subsequent screen, differences in sensitivity of 
the cell lines and their respective sublines towards the 
identified drugs were analyzed in 8-point dose-response 
curves (3-fold dilutions typically starting at 13.5μM, 
0.135% DMSO, 13.5μM Bortezomib served as positive 
control). A mean Z-factor of 0.277756 was calculated 
over all plates [48]. Areas under the curve (AuC) were 
calculated as a cumulative measure of compound potency 
by doing the sum of the mean of subsequent concentration 
points. Hits were defined as a 50% difference in viability 
at one concentration or a similar cumulative effect over 
all concentrations and 1 standard deviation difference 
between the two means. According to these criteria, 39 
compounds were identified as differentially cytotoxic in 
at least one of the three cell line pairs.
Whole genome gene expression array
Whole genome gene expression arrays were 
performed on 4x44K whole genome oligonucleotide-
based gene expression arrays (Agilent, Santa Clara, USA) 
as previously described [49, 50]. For data analysis, signal 
intensity values were filtered according to sufficient- 
(>20 raw expression values) and significant differences 
in expression by GeneSpring software (analyzed by 
unpaired t-test - Benjamini-Hochberg correction, p-value 
cut-off: 0.05). Differentially expressed genes were further 
analyzed by gene set enrichment analysis (GSEA) and 
were normalized in R using Robust Multi-Array Average 
Normalization Approach (http://www.broadinstitute.org/
gsea/msigdb/index.jsp).
Ectopic overexpression of ABCB1 by plasmid 
DNA transfection
DMS114 cells were transfected with peYFP-
ABCB1 plasmid DNA using XFect Transfection Reagent 
(Clontech, Mountain View, USA) according to the 
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manufacturer's recommendations. peYFP-C1 served as 
a negative control vector. ABCB1 overexpression was 
monitored after 72 hours by qPCR.
Calcein AM assay
Cells were harvested after trypsinization by 
centrifugation at 500xg and resuspended in serum-free 
medium. Calcein AM (0.25μM) was added to 3×105 cells 
in 4mL medium in the presence or absence of 10μM 
verapamil, elacridar or nintedanib and samples incubated 
for 15 minutes at room temperature. Reactions were 
stopped by centrifugation and resuspension in ice-cold 
PBS. Fluorescence of intracellular Calcein was measured 
using a BD FACS-Calibur flow cytometer. The well-
known ABCB1 modulators elacridar and verapamil were 
used as controls.
ABCB1 ATPase activity
Crude cell membranes purified from Spodoptera 
frugiperda (Sf9) cells expressing ABCB1 were prepared as 
described earlier [18]. Vanadate-sensitive ATPase activity 
was measured by following the release of inorganic 
phosphate using a colorimetric reaction.
Rhodamine (Rh123) accumulation assay
Intracellular accumulation of the ABCB1 substrate 
Rh123 was determined in DMS114, DMS114/NIN, KB-
3-1 and KBC-1 as previously described [19]. Briefly, 
5x105 cells were resuspended in serum-free RPMI 
1640/HEPES medium containing 3-(N-morpholino)
propanesulfonic acid MOPS (Sigma) and pretreated with 
indicated concentrations of elacridar or nintedanib for 
30 minutes at 37°C. After 1h incubation with Rh123 at 
room temperature, intracellular Rh123 fluorescence was 
measured by flow cytometry (FACSCalibur). The ABCB1 
modulator elacridar was used as control.
HPLC-MS
5x105 cells were seeded in 6-well plates and 
incubated overnight. After 15 minutes preincubation with 
the selective ABCB1 inhibitor elacridar (10μM), cells 
were incubated with 1μM nintedanib for 10 or 60 minutes 
at 37°C. Transport reaction was stopped by addition of 
ice-cold PBS. Cells were pelleted, washed with ice-cold 
PBS three times and precipitated with 50μl acetonitrile 
(Sigma). After centrifugation at 8000xg for 5 minutes, 
supernatant was transferred into fresh tubes. Quantitation 
measurements were run on an AB Sciex 3200QTrap 
hybrid tandem mass spectrometer coupled to the Perkin 
Elmer S200 HPLC system consisting of binary pumps, 
autosampler and column oven. A Thermo BetaBasic C8 
(50 x 3 mm, 3μm particle size) column was used for 
separation. Gradient elution was applied by using 0.1% 
formic acid in water and 0.1% formic acid in acetonitrile.
siRNA knockdown of PKC
5x105 cells were transfected with Lipofectamine 
2000 (Invitrogen, Carlsbad, USA) using 50nM of PKC 
siRNA (Santa Cruz Biotechnology) or an equimolar 
concentration of scrambled siRNA (Dharmacon, Lafayette, 
USA) according to the manufacturer's recommendations. 
Downregulation of PKC expression was monitored at 
the protein level by Western blot 48 and 72 hours post 
transfection.
Statistical analysis
If not stated otherwise, data are expressed as mean 
± SD. Results were analyzed using GraphPad Prism 
software. Statistical analyses were performed using t-test 
or two-way analysis of variance (ANOVA). To examine 
differences between drug treatment responses, Bonferroni 
post-tests were conducted. P values below 0.05 were 
considered as statistically significant and marked with 
stars: * p<0.05; ** p<0.01; *** p<0.001.
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